Companies adhering to the "market segmentation, maximize share" business philosophy, clear business development direction. The main products are contrast agent series, psychoneurological products and hypoglycemic products. As the earliest enterprise to develop and launch contrast agent products in China, we have provided a series of high-quality, safe and reasonable-priced products for the market through technological innovation and process improvement, which has promoted the clinical application and development of contrast agent products in China. The company's products have formed a unique core competitive advantage in this field, with high popularity and market influence, and the products cover hospitals in all provinces, cities and above the county level. Hokuriku pays attention to the quality training of marketing personnel and the improvement of professional level. In order to better serve doctors and patients, it has gradually established a stable and experienced marketing team.
Companies adhere to the people-oriented, respect, understand, care and care for employees in management. Cultivate employees' sense of corporate responsibility, social responsibility and family responsibility. Encourage employees to innovate hard and form a stable and harmonious internal environment. At the same time, efforts should be made to create a corporate culture with the characteristics of Hokuriku from the aspects of value concept and behavior rules.
The company advocates innovative and rigorous work style, and has achieved success after success in the past. For many years, it has been rated as an A-level enterprise with tax credit and one hundred innovative pilot enterprises in Zhongguancun. Won the national invention patent, national new product certificate, Beijing science and technology progress award and other honors; The main products have also been included in the national torch plan, Beijing torch plan, major industrialization projects in Beijing, etc. , and get financial support at all levels; On 20 10, the company was officially selected as the first batch of large-scale enterprises in Beijing Biomedical Industry Leaping Development Project (G20 Project); In 20 10, China Academy of Social Sciences, China Medical Information Professional Committee and well-known experts in the industry participated in the selection activities, and were named "Top 50 enterprises in the list of core competitiveness of pharmaceutical listed companies".
On June 30th, 2009, 10, the company was officially listed on the Growth Enterprise Market of Shenzhen Stock Exchange as one of the first 28 enterprises, with the stock code: 3000 16, and the company embarked on a new development platform. In the future, through technological innovation, management innovation, professional academic promotion and fund-raising project construction, the company will comprehensively enhance its new drug research and development capabilities, production capacity, operational efficiency, market share and profitability, and consolidate and improve its core competitiveness.
Beijing Beiliu Pharmaceutical Co., Ltd., formerly known as Beijing Haidian Beiliu Pharmaceutical and Chemical Company, was established in Zhongguancun Science Park, 1992. Beijing Beiliu Pharmaceutical Co., Ltd. was established by Beijing Beiliu Pharmaceutical Co., Ltd. on 200 1 as a whole. The sponsors are Beijing Science and Technology Venture Capital Co., Ltd., Chongqing Three Gorges Coatings Co., Ltd., Wang Daixue, Hong Wei and Yao Zhenping. On February 8, 200 1 year, the business license of enterprise as a legal person was obtained.